S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Metastatic Gastric Adenocarcinoma Clinical Trial

Official title:

S1 Plus Paclitaxel (IV&IP) Plus Bevacizumab (IP) Versus S1 Plus Oxaliplatin(IV) as First-line Treatment in Gastric or Gastroesophageal Junctional Adenocarcinoma With Malignant Ascites: An Open-label, Multicenter Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03990103
• Other study ID #: CLOG1704
• Status: Recruiting
• Phase: Phase 2
• Start date: November 1, 2017
• Est. completion date: April 30, 2022

Study information

• Verified date: June 2019
• Source: China Medical University, China
• Contact: Yunpeng Liu, M.D.
• Phone: 86-24-83282312
• Email: cmu_trial[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection & intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs. S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites.

Description:

This is a prospective, open-label, multicenter clinical trial, to compare the efficacy of S1 plus paclitaxel (intravenous injection & intraperitoneal injection) plus bevacizumab (intraperitoneal injection) versus S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites. A total of 66 patients who are diagnosed with gastric or gastroesophageal junctional adenocarcinoma will be allocated to receive either S1 orally administration plus paclitaxel intravenous injection & intraperitoneal injection plus bevacizumab intraperitoneal injection, or to receive S1 orally administration plus oxaliplatin intravenous injection. The primary end point is ascites response rate at 6 weeks. The secondary end points include the median overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), objective response rate (ORR), puncture free survival, volume of drainage, the quality of life (QoL) and safety.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: April 30, 2022
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18 years = Age= 70 years, male or female

• Pathologically confirmed adenocarcinoma of the gastric or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease; with medium amount of malignant ascites which can be catheterized.

• Diagnostic criteria for malignant ascites (meet any of the following criteria):

ascites cytology positive; or imaging or pathological confirmed peritoneal metastases.

• No prior anti-tumor treatment to the metastatic disease; an interval of at least 6 months from the last adjuvant chemotherapy.

• Eastern Cooperative Oncology Group (ECOG) performance status( PS) score 0-1.

• Normal major organ function, and laboratory tests must meet the following criteria:

hemoglobin (HGB) = 90 g/L, neutrophil count = 1.5×109/L, platelet count = 100×109/L, total bilirubin (TBil) = 1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 UNL, serum creatinine (Cr) = 1 UNL; creatinine clearance rate (CCr) = 60 ml/min (calculated using the Cockcroft-Gault equation).

• International Normalized Ratio (INR) = 1.5 and partial prothrombin time (PPT) or activated partial thromboplastin time (APTT) = 1.5 UNL within 7 days before enrollment.

• Life expectancy of at least 12 weeks

• Signed informed consent (ICF)

• For women of child bearing potential, a negative serum or urine pregnancy test result should be obtained with 7 days before enrollment; Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration.

Exclusion Criteria:

• Known hypersensitivity or allergic to any of the study drugs, study drug classes, or excipients in the formulation.

• Subject received chemotherapy to the metastatic disease (except adjuvant/neoadjuvant chemotherapy administered 24 weeks before enrollment)

• Subject with other malignancies, except for non-melanoma skin cancer or in-situ cervical carcinoma under adequate treatment, or other treated malignancies without evidence of recurrent for 5 years.

• Anti-tumor cytotoxic drug therapy within 14 days prior to enrollment(longer washout time interval might needed depends on drug characteristics)

• Uncontrolled hypertension which cannot be reduced to normal range by antihypertensive agents [Systolic Blood Pressure(SBP) >140 mmHg, diastolic blood pressure (DBP) > 90 mmHg], coronary artery disease > grade 1, arrhythmia > grade 1 [including corrected QT(QTc) interval prolongation: QTc>450 ms for male,QTc>470 ms for female], grade 1 heart failure.

• Proteinuria = ++,or persistent proteinuria > 1.0 g/24 hours

• Presence of any toxicity = grade 1 according to NCI-CTCAE except for alopecia.

• Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks, cerebral hemorrhage?cerebral infarction), deep vein thrombosis and pulmonary embolism within 12 months before enrollment.

• Bowel obstruction within 6 weeks before enrollment.

• Surgical treatment was performed within 6 weeks before enrollment. Subject should recover from any major surgery.

• Serious uncontrolled systemic illness or medical condition or uncontrolled infections, including but not limited to: uncontrollable ventricular arrhythmias, history of documented myocardial infarction within 3 months, uncontrollable epileptic dementia, unstable spinal compression, superior vena cava syndrome, extensive bilateral interstitial pulmonary disease by high-resolution computed tomography (HRCT), or any neurological or mental abnormalities which affect compliance.

• Human immunodeficiency virus (HIV) positive

• Pregnancy or lactation women

• Cannot be orally administered medication

• Subject with a tendency for gastrointestinal hemorrhage. Including: Black stool or hematemesis within 2 months; For subjects positive in occult test with unresected primary lesion, if the principle investigator in each center considers with possibility of gastrointestinal hemorrhage, the subject could not be enrolled.

• Subject with malignant pleural effusion need medical intervention.

• A history or evidence of hereditary hemorrhagic constitution or coagulation disorder that increases the risk of bleeding

• Subjects with central nerve system metastases

• Have been enrolled in other clinical trial with investigational drug treatment within the 4 weeks of start of study treatment

• For subject with bone metastases, palliative radiotherapy was given 4 weeks before enrollment (radiation field >5%).

• Any other disease or condition that the investigator considers not suitable for participating in this clinical trial.

Related Conditions & MeSH terms

• Adenocarcinoma
• Ascites
• Metastatic Gastric Adenocarcinoma

Intervention

Drug:
• S1
80-120 mg/day, PO, D1-14, every 21 days
• Paclitaxel
20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
• Bevacizumab
200 mg, IP, D1, every 21 days
• Oxaliplatin
130 mg/m2, IV, D1, every 21 days

Locations

Country	Name	City	State
China	The First Affiliated Hospital of China Medical University	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ascites response rate at 6 weeks	response of ascites at 6 weeks	6 weeks
Secondary	PFS	Progression-free survival,From 1st drug administration to the date of first progression or date of death (whichever occurs first)	12 months
Secondary	OS	Overall survival, from enrollment until death from any cause	2 years
Secondary	ORR	Objective response rate, the proportion of patients with reduction in tumor burden of a predefined amount	12 months
Secondary	TTF	Time to treatment failure, from 1st drug administration to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death	12 months
Secondary	Puncture free survival	Puncture free survival time, from the first puncture to secondary puncture	12 months
Secondary	Volume of drainage	Volume of drainage	12 months
Secondary	Adverse events	Adverse events	12 months